
Working Women's Well-Being Is Declining Faster Than Men's, A New Book Argues. Here's What We Can Do About It—and How 'It Makes Better Business Sense'
In This Isn't Working: How Working Women Can Overcome Stress, Guilt and Overload to Find True Success—which is out August 5—French Dunbar argues that, by improving workplaces for women, it will not only boost performance for them but also everyone; that burnout isn't a badge of honor anymore; and that, right from the book's dedication page, women 'no longer have to abide by the status quo but can, instead, redefine it.'
It's a problem that many women find themselves in: by any measure, French Dunbar was successful, but behind the scenes, she was struggling. Though she was 'doing everything right,' she didn't feel right. The pressure was too much; she had burned out. She resigned as CEO of the organization she founded on February 1, 2020. Her last day was March 13—and then COVID-19 struck.
'I was such a high achiever and had been so conditioned to 'This is what success is, and that's what worth is,'' she tells me over Zoom. 'And COVID just stripped me of that.' She adds, 'I mean, COVID was the worst of times for many of us, and there was also a lot of beauty in the forced pause in a lot of people's lives.'
At the time, she had a 9-month-old son and was about to launch an in-person events company. Like so many women, French Dunbar knew busyness intimately. 'The traditional success track was just forced to be put on hold, and I had to stop, and it was a very long process, but I had this moment where I realized that I had no identity or sense of self-worth in the absence of professional accomplishment,' she says. This isn't working. She realized 'I don't want to completely destroy myself in the name of success and work nights and weekends and sacrifice all my relationships,' she says. And that's where the origin of her new book begins.
'The process of writing the book was just such a gift, because I got to interview extraordinary women who are also thriving,' French Dunbar says. 'And so many of them talked about setting boundaries and not tying every sense of worth to your achievement and all of the elements that just got reinforced over and over and over again.'
French Dunbar writes in the book that there are a disproportionate amount of women experiencing burnout and stress. 'Working women's well-being is declining faster than men's, regardless of whether they have children,' she notes in the book. An estimated 43 percent of women report feeling burned out, compared to 31 percent of men at the same level. Women's symptoms of depression significantly increase as their authority increases, she further points out, while symptoms of depression in men tend to decrease. On Zoom, she further accentuates the statistic that 75 percent of high-performing women receive negative feedback, as opposed to 2 percent of men. This isn't working.
'I desperately wanted to understand why working women were disproportionately struggling and if there was a better way,' French Dunbar writes in the book. She wanted to replace the traditional leadership playbook with a new leadership playbook.
'The way that you show up at work every single day impacts everybody around you,' she tells me. 'And this is why you need to build healthy, thriving organizations so that everyone is healthy and thriving and that people aren't making each other miserable as a result of coming to work.'
It was comforting for French Dunbar to learn that it was the system, not her, that was deficient: 'For me, it felt so validating because, of course, we're women and we're always blaming ourselves and 'I'm not good enough,'' she tells me. When it comes to women, 'we're struggling,' she adds. 'We're struggling in a system that harms the majority of the people, the majority of the labor force—nearly 4 billion people worldwide. Most people are dealing with chronic stress, burnout, some sort of mental or physical health issue as a result of work-related stress in that system. Women, then, are contending with all of these additional barriers, and that is why we have increased risks of chronic stress, anxiety, burnout, all of the other issues. When I understood that, I was like, 'Oh, that means that when we succeed in this system, we're actually extraordinary.''
'When you look at the data of the odds that you're going to succeed within the system, there's a reason that you're feeling the way you're feeling if you're stressed and overwhelmed and all the things,' French Dunbar says to a very relieved me. 'And you're absolutely incredible that you've been succeeding in this system, because everything is ripping against you.'
French Dunbar had been in what she calls 'the hamster wheel of achievement addiction' for a very long time, and the walls eventually crumbled down around her. 'I was so burned out and so miserable that I had to walk away from my own company that I loved,' she says. 'And that is a very common story that I hear, is pushing yourself so far until people are hospitalized or having breakdowns, having panic attacks and then going to work the next day being like, 'That's totally normal. Everyone around me is having panic attacks. It's totally fine.''
Spoiler alert: it's not totally fine. The book teaches readers a new way forward, one that, when everyone—including and especially women—in the workplace feels better, it actually improves the company's performance. This is good not just for employees' quality of life, but 'it makes better business sense,' French Dunbar says.
One of many examples of a mindset shift from the book? It's one that French Dunbar says she's 'having the hardest time practicing what I preach'—the 'relentless pursuit of achievement and tying your self-worth to that and getting so busy that you don't even know who you are anymore,' she says. (Yep. Been there.) 'We are so busy that we don't even have the time to check in on how we are actually doing.'
The reframe? A tool from Stanford psychologist Carol Dweck, who delineates the difference between performance goals and learning goals, with an emphasis on the latter. 'A performance goal is like, 'I want an A in French,' and a learning goal is 'I want to learn French,'' French Dunbar says. 'And so, with something like a book or your career, not everything has to be about your next title or the salary or The New York Times bestseller list. It is like, 'I'm doing this for the experience of gaining knowledge, having experiences and enriching who I am as a human,' instead of, 'I will only consider this to be a successful thing if it hits these certain milestones.''
Releasing the relentless pursuit of achievement 'has been a big one for me,' she says, and learning that 'you matter and you are worthy just as you are'—regardless of achievement.
The first step, she tells me, is admitting there's a problem and that the current work culture that society has isn't okay. Check. The book takes readers through what to do next.
'Your stress, your overwhelm, your exhaustion, your burnout—that is not on you,' French Dunbar says. 'That's not a you problem. It's a cultural problem of the way that we're doing business.' But, she adds, 'It can be done in such a better way. There are extraordinary humans who have already done this and have already written the blueprint.'
That blueprint makes up the pages of This Isn't Working. Above all else, Dunbar says? When readers close the book, no matter how burned out or exhausted or overwhelmed they are, she wants this to be made clear: 'There is hope,' she says.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
The Hidden Lung Infection Impacting Millions: World NTM Day Puts Spotlight on Awareness
With Annual NTM Case Rates Rising, Patients and Providers Are Urged to Recognize the Symptoms and Risks MIAMI, Aug. 4, 2025 /PRNewswire/ -- As the world prepares to observe World NTM Day on August 4, 2025, NTM Info & Research (NTMir) is calling on patients, physicians, caregivers, and policy leaders to shine a spotlight on nontuberculous mycobacterial (NTM) lung disease, a growing but underrecognized threat to global respiratory health. Experience the full interactive Multichannel News Release here: NTM lung disease is caused by environmental bacteria found in water and soil. While many are exposed, people with underlying lung conditions—particularly bronchiectasis—are at higher risk of infection. Alarmingly, new data show that NTM cases are rising by more than 8.2% annually, particularly among women over age 65 and individuals with chronic lung disease. The economic burden per patient can exceed $30,000 per year, underscoring the cost of delayed diagnosis and limited treatment options. "NTM lung disease is one of the most misunderstood and misdiagnosed conditions we see today," said Amy Leitman, JD, President of NTMir. "It doesn't just threaten lives—it disrupts them. But the earlier we recognize the symptoms, the better our chances of preventing severe lung damage and improving patient outcomes." Most people diagnosed with NTM also have bronchiectasis, a condition that causes permanent damage to the airways. When combined, the diseases can lead to a vicious cycle of recurring infections, declining lung function, and years of missed opportunities for proper care. "We want to empower people to listen to their lungs," said Leitman. "If someone is experiencing persistent coughing, fatigue, shortness of breath, or unexplained weight loss—don't wait. Ask your doctor if NTM could be the cause." World NTM Day: Raising Voices, Inspiring Action This year's theme, "Recognize. Respond. Rise Together," emphasizes the critical need for: Early diagnosis through improved screening protocols Patient education and community engagement Investment in research and innovation to support more effective and accessible treatments To that end, NTMir continues to lead efforts to: Deliver comprehensive educational resources on diagnosis, treatment, and ongoing clinical research Support a global network of patients and caregivers through online communities and local support groups Advocate for increased research funding and policy change to address the unmet needs of the NTM community Visit for patient stories, educational tools, clinical trial information, and ways to take action. How You Can Help: Learn the symptoms and risk factors by visiting Share social media posts, videos, and infographics using #WorldNTMDay2025 Join a support group or community event near you Encourage your healthcare providers to consider NTM in patients with unexplained respiratory symptoms Together, we can improve outcomes, expand awareness, and give a stronger voice to those living with NTM lung disease. About NTM Info & Research (NTMir):NTM Info & Research (NTMir) is a national 501(c)(3) non-profit organization formed on behalf of patients with pulmonary nontuberculous mycobacterial (NTM) disease for patient support, medical education and research. The organization serves patients, healthcare providers and researchers dealing with bronchiectasis and NTM. It advocates a broad agenda to promote early diagnosis, improved treatments, and research. The mission is to bring a voice to the concerns of all our constituents with government officials and agencies that guide, research, and regulate therapies developed to treat these diseases. NTM Info & Research recognizes the need for advancement in education and treatment of bronchiectasis. About World NTM Day 2025: World NTM Day, observed annually on August 4, is a global awareness initiative led by NTM Info & Research (NTMir) to spotlight the rising impact of nontuberculous mycobacterial (NTM) lung disease—a serious and often misunderstood condition that affects tens of thousands each year. The 2025 theme, "Recognize. Respond. Rise Together," underscores the urgent need to increase awareness, improve early detection, and empower patients and providers with knowledge. As NTM cases continue to climb and too many remain undiagnosed or misdiagnosed, World NTM Day calls on the global community to take action—by learning the signs, supporting those affected, and advancing research that brings hope for better outcomes. View original content: SOURCE NTM Info & Research (NTMir) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Drug Farm Announces First Patients Dosed in Phase 1b Clinical Trial Evaluating ALPK1 Inhibitor, DF-003 in ROSAH Syndrome
Trial will evaluate DF-003, a first-in-class ALPK1 inhibitor that specifically targets the genetic root cause of ROSAH syndrome ALBANY, N.Y. & SHANGHAI, August 04, 2025--(BUSINESS WIRE)--Drug Farm, a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop innovative, immune-modulating therapies, today announced that the first human participants have been dosed in a clinical trial (NCT06395285) of DF-003 in patients with ROSAH syndrome. DF-003 is a first-in-class, immune-modulating alpha-kinase 1 (ALPK1) inhibitor that targets ALPK1 mutants causing ROSAH syndrome. The trial is evaluating the safety, pharmacokinetics and efficacy of orally administered DF-003 at sites in the USA and Australia. "We are happy to offer patients with ROSAH syndrome the opportunity to participate in a clinical trial using a new precision-targeted drug to treat the root cause of their disease," said Dr. John Grigg, Professor of Clinical and Experimental Ophthalmology, Save Sight Institute Faculty of Medicine and Health at The University of Sydney. "The initiation of this trial is a critical step forward in our goal to provide a therapeutic option in disease indications with unmet medical need that are mediated by excessive ALPK1 activation," said Henri Lichenstein, PhD, Chief Executive Officer of Drug Farm. "We are optimistic about the potential of DF-003 to make a meaningful difference in the lives of patients with ROSAH, and together with our collaborators, are committed to thoroughly investigating the safety and efficacy of DF-003 in patients with atherosclerotic cardiovascular disease as well." About DF-003 DF-003 is a proprietary, first-in-class drug developed by Drug Farm that inhibits the activity of ALPK1 and variants of ALPK1 which cause ROSAH syndrome. DF-003 has therapeutic potential for ROSAH syndrome, as well as heart and kidney diseases, as the drug has shown efficacy in preclinical models of these indications. DF-003 has completed a Phase 1 clinical trial (NCT05997641) in normal healthy volunteers and is now accruing patients with ROSAH syndrome in a Phase 1b trial (NCT06395285). About ROSAH Syndrome ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome is a rare, autosomal dominant autoinflammatory genetic disease named according to the characteristic symptoms exhibited by affected patients (1, 2). Disease-causing mutations in ALPK1 lead to ROSAH syndrome. The most common presenting symptom is a progressive decline in visual acuity that typically begins before 20 years of age, with ophthalmologic examination often revealing optic disc elevation, uveitis, and retinal nerve degeneration (2, 3). Most ROSAH patients also exhibit inflammatory features such as non-infectious low-grade fevers, arthralgia, headaches, and persistently elevated levels of inflammatory cytokines including tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), and IL-1β (3). 1. Tantravahi SK, et al. An inherited disorder with splenomegaly, cytopenias, and vision loss. Am J Med Genet A. 2012;158(3):475-81. 2. Williams LB, et al. ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. Genet Med. 2019;21(9):2103-15. 3. Kozycki CT, et al. Gain-of-function mutations in ALPK1 cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome. Ann Rheum Dis. 2022;81(10):1453-64. About Drug Farm Drug Farm is a private biotechnology Company developing innovative treatments targeting innate immunity for hepatitis B, heart and kidney diseases, and ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: View source version on Contacts United States:Henri Lichenstein, Executive OfficerEmail: hlichens@ China:Tony Xu, and Chief Operating OfficerEmail: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
DURHAM, N.C., August 04, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA such as in the HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the DMD program). View source version on Contacts Investor and Media Contact: Naresh TannaVice President of Investor